International Expert-Based Consensus Definition, Classification Criteria, and Minimum Data Elements for Osteoradionecrosis of the Jaw: An Inter-Disciplinary Modified Delphi Study.

Purpose: Osteoradionecrosis of the jaw (ORNJ) is a severe iatrogenic disease characterized by bone death after radiation therapy (RT) to the head and neck. With over 9 published definitions and at least 16 classification systems, the true incidence and severity of ORNJ are obscured by lack of a standard for disease definition and severity assessment, leading to inaccurate estimation of incidence, reporting ambiguity, and likely under-diagnosis worldwide. This study aimed to achieve consensus on an explicit definition and phenotype of ORNJ and related precursor states through data standardization to facilitate effective diagnosis, monitoring, and multidisciplinary management of ORNJ.

A Rare Case of Low-Grade Appendiceal Mucinous Neoplasm Presenting As Mucinous Vaginal Discharge.

Appendiceal mucinous neoplasms (AMNs) are rare tumors that often present with non-specific symptoms, posing diagnostic challenges. This report aims to emphasize the importance of considering AMNs in the differential diagnosis of atypical pelvic symptoms, especially when initial evaluations suggest gynecological issues. A 56-year-old female with a past medical history of hyperlipidemia and a total vaginal hysterectomy performed over 20 years prior for abnormal uterine bleeding due to fibroids presented to her gynecologist with a three-week history of vaginal discharge and pelvic pain.

Radiotherapy with cetuximab or durvalumab for locoregionally advanced head and neck cancer in patients with a contraindication to cisplatin (NRG-HN004): an open-label, multicentre, parallel-group, randomised, phase 2/3 trial.

Background: Management of patients with locoregionally advanced head and neck squamous cell carcinoma (HNSCC) when cisplatin is contraindicated is controversial. We aimed to assess whether radiotherapy with concurrent and adjuvant durvalumab would improve outcomes compared with radiotherapy with cetuximab.

Methods: NRG-HN004 was designed as an open-label, multicentre, parallel-group, randomised, phase 2/3 trial with safety lead-in conducted at 89 academic and community medical centres in North America.